Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 14/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2950773 | 0.99 | HDAC8 (0.54) | HDAC8HDAC6MCHR1MRGPRX4PKM | |
| SCHEMBL2953131 | 0.88 | HDAC8 (0.49) | HDAC8HDAC6MCHR1ROCK2 | |
| SCHEMBL2950684 | 0.87 | HDAC8 (0.57) | HDAC8HDAC6MCHR1ALDH1A1CYP1A2 | |
| SCHEMBL2954604 | 0.87 | MCHR1 (0.59) | HDAC8HDAC6MCHR1ALDH1A1CYP1A2 | |
| SCHEMBL2948748 | 0.87 | HDAC8 (0.57) | HDAC8HDAC6MCHR1MRGPRX4ALDH1A1 | |
| SCHEMBL2960992 | 0.87 | HDAC8 (0.45) | HDAC8HDAC6MCHR1PKMALDH1A1 | |
| SCHEMBL2956165 | 0.84 | HDAC8 (0.60) | HDAC8HDAC6MCHR1MRGPRX4ALDH1A1 | |
| SCHEMBL2950864 | 0.84 | HDAC8 (0.60) | HDAC8HDAC6MCHR1ALDH1A1CYP1A2 | |
| SCHEMBL2959882 | 0.84 | HDAC8 (0.54) | HDAC8HDAC6MCHR1ALDH1A1CYP1A2 | |
| SCHEMBL2953612 | 0.84 | HDAC8 (0.56) | HDAC8HDAC6MCHR1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247741-B2 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | claimed |
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | claimed |
| US-7763656-B2 | Use of Acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070203123-A1 | Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-7247741-B2 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1525185-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004009533-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | UPF1, NAT10, PABPC1 | HDAC8 789/4885HDAC6 393/4885MCHR1 3950/4885 |
| US-20070203123-A1 | Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | UPF1, NAT10, PABPC1 | HDAC8 980/4885HDAC6 656/4885MCHR1 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.